Financials data is unavailable for this security.
View more
Year on year Par Drugs and Chemicals Ltd had relatively flat revenues (957.49m to 956.40m), though the company grew net income 27.94% from 113.34m to 145.01m. A reduction in the cost of goods sold as a percentage of sales from 69.35% to 35.33% was a component in the net income growth despite flat revenues.
| Gross margin | 66.84% |
|---|---|
| Net profit margin | 15.28% |
| Operating margin | 20.37% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Par Drugs and Chemicals Ltd increased its cash reserves by 64.79%, or 144.11m. The company earned 202.49m from its operations for a Cash Flow Margin of 21.17%. In addition the company used 58.38m on investing activities while cash flow from financing was even.
| Cash flow per share | 14.68 |
|---|---|
| Price/Cash flow per share | 16.59 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in earnings per share excluding extraordinary items increased 27.89%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| EPS growth(5 years) | 16.02 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 26.37 |
